 Patients will be evaluated for inclusion during a ScreeningBaseline period of up to 4 weeks. Eligible patients will receive once weekly intravenous IV infusions of 30 mgkg eteplirsen for 96 weeks, followed by a safety extension not to exceed 48 weeks. 